Dougherty & Co Starts AtriCure Inc. (ATRC) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Starts AtriCure Inc. (ATRC) at Buy
March 9, 2015 6:20 AM EDTNeedham & Company initiates coverage on AtriCure Inc. (NASDAQ: ATRC) with a Buy rating and a price target of $21.00.
Analyst Mike Matson commented, "ATRC is the leader in surgical treatment of atrial fibrillation (AF) and left atrial appendage (LAA) occlusion. Its growth... More
